Skip to main content
3
Talking with Titans of Psychopharmacology

From the 2025 American Psychiatric Association (APA) Annual Meeting, Psychiatric Times' Editor in Chief, John J. Miller, MD, interviews Jonathan M. Meyer, MD, DFAPA
Learn More

Our Mission

At Saladax, we develop and manufacture therapeutic drug monitoring (TDM) assays
for essential and life-saving medications prescribed by psychiatrists and oncologists. These assays ensure that each and every patient receives their optimal dose.

General NewsOncology NewsPsychiatry News
April 7, 2026

Saladax Biomedical to Expand International Access to Drug Level Testing for Psychiatry and Oncology

Bethlehem, PA, April 07, 2026 (GLOBE NEWSWIRE) -- Saladax Biomedical, Inc., a leader in therapeutic drug monitoring (TDM) diagnostics for psychiatry and oncology, today announced a distribution agreement with Thermo…
John Buckley
Love0
Oncology News
June 5, 2024

Health Canada Approves Saladax’s 5-Fluorouracil Chemotherapy Therapeutic Drug Monitoring (TDM) Test

Bethlehem, PA – May 14, 2024 – Saladax Biomedical, Inc. (Saladax) is pleased to announce that Health Canada has approved Saladax’s 5-Fluorouracil (My5-FU) Assay for sale in Canada in a…
John Buckley
Love0
Psychiatry News
July 24, 2023

Determining Clozapine Response vs. Nonresponse

Determining Clozapine Response vs. Nonresponse Recorded in July 2023 at Saladax’s first Virtual Product Theater in conjunction with AAPP Description: When treating patients with clozapine, it is essential to distinguish…
John Buckley
Love0
Psychiatry News
November 8, 2022

Antipsychotic Finger Prick Test Shows Drastic Wait Reduction

Originally posted at Med-Tech, please view the article at this link. The new finger prick test, provided by Saladax Biomedical, reduces the need for traditional blood testing, cutting the time…
John Buckley
Love0

Request Information

Please fill out the form and we will contact you.


This will close in 20 seconds

This will close in 20 seconds